VNDA » Topics » Year ended December 31, 2008 compared to year ended December 31, 2007

These excerpts taken from the VNDA 10-K filed Apr 29, 2009.
Year ended December 31, 2008 compared to year ended December 31, 2007
 
Net cash used in operations was approximately $46.0 million for the year ended December 31, 2008 and $51.6 million for the year ended December 31, 2007. The net loss for the year ended December 31, 2008 of approximately $51.1 million was offset primarily by non-cash charges for depreciation and amortization of approximately $531,000, stock-based compensation of approximately $13.4 million, and decreases in accrued expenses and accounts payable of approximately $9.4 million, principally related to clinical trial expenses. Net cash provided by investing activities for the year ended December 31, 2008 was approximately $43.1 million and consisted primarily of net maturities and sales of marketable securities of approximately $44.0 million. There was no net cash provided by financing activities for the year ended December 31, 2008.
 
Year
ended December 31, 2008 compared to year ended
December 31, 2007



 



Net cash used in operations was approximately $46.0 million
for the year ended December 31, 2008 and $51.6 million
for the year ended December 31, 2007. The net loss for the
year ended December 31, 2008 of approximately
$51.1 million was offset primarily by non-cash charges for
depreciation and amortization of approximately $531,000,
stock-based compensation of approximately $13.4 million,
and decreases in accrued expenses and accounts payable of
approximately $9.4 million, principally related to clinical
trial expenses. Net cash provided by investing activities for
the year ended December 31, 2008 was approximately
$43.1 million and consisted primarily of net maturities and
sales of marketable securities of approximately
$44.0 million. There was no net cash provided by financing
activities for the year ended December 31, 2008.


 




These excerpts taken from the VNDA 10-K filed Mar 13, 2009.
Year ended December 31, 2008 compared to year ended December 31, 2007
 
Net cash used in operations was approximately $46.0 million for the year ended December 31, 2008 and $51.6 million for the year ended December 31, 2007. The net loss for the year ended December 31, 2008 of approximately $51.1 million was offset primarily by non-cash charges for depreciation and amortization of approximately $531,000, stock-based compensation of approximately $13.4 million, and decreases in accrued expenses and accounts payable of approximately $9.4 million, principally related to clinical trial expenses. Net cash provided by investing activities for the year ended December 31, 2008 was approximately $43.1 million and consisted primarily of net maturities and sales of marketable securities of approximately $44.0 million. There was no net cash provided by financing activities for the year ended December 31, 2008.
 
Year
ended December 31, 2008 compared to year ended
December 31, 2007



 



Net cash used in operations was approximately $46.0 million
for the year ended December 31, 2008 and $51.6 million
for the year ended December 31, 2007. The net loss for the
year ended December 31, 2008 of approximately
$51.1 million was offset primarily by non-cash charges for
depreciation and amortization of approximately $531,000,
stock-based compensation of approximately $13.4 million,
and decreases in accrued expenses and accounts payable of
approximately $9.4 million, principally related to clinical
trial expenses. Net cash provided by investing activities for
the year ended December 31, 2008 was approximately
$43.1 million and consisted primarily of net maturities and
sales of marketable securities of approximately
$44.0 million. There was no net cash provided by financing
activities for the year ended December 31, 2008.


 




RELATED TOPICS for VNDA:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki